tradingkey.logo
tradingkey.logo
Search

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy

ReutersApr 29, 2025 12:23 PM
facebooktwitterlinkedin

- Travere Therapeutics Inc TVTX.O:

  • TRAVERE THERAPEUTICS AND CSL VIFOR ANNOUNCE STANDARD EU APPROVAL OF FILSPARI® (SPARSENTAN) FOR IGA NEPHROPATHY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI